Literature DB >> 19142405

Mild cognitive impairment: cognitive screening or neuropsychological assessment?

Breno Satler Diniz1, Paula Villela Nunes, Monica S Yassuda, Fernanda S Pereira, Mariana K Flaks, Luciane F Viola, Marcia Radanovic, Izabella Dutra de Abreu, Danilo T Borelli, Wagner F Gattaz, Orestes Vicente Forlenza.   

Abstract

OBJECTIVE: To describe the neuropsychological profile of mild cognitive impairment subtypes (amnestic, non-amnestic and multiple-domain) of a clinical sample. We further address the diagnostic properties of the Mini-Mental State Examination and the Cambridge Cognitive Examination for the identification of the different mild cognitive impairment subtypes in clinical practice.
METHOD: Cross-sectional clinical and neuropsychological evaluation of 249 elderly patients attending a memory clinic at a university hospital in Sao Paulo, Brazil.
RESULTS: The performance of patients with mild cognitive impairment was heterogeneous across the different subtests of the neuropsychological battery, with a trend towards an overall worse performance for amnestic (particularly multiple domain) mild cognitive impairment as compared to non-amnestic subtypes. Screening tests for dementia (Mini-Mental State Examination and Cambridge Cognitive Examination) adequately discriminated cases of mild Alzheimer's disease from controls, but they were not accurate to discriminate patients with mild cognitive impairment (all subtypes) from control subjects.
CONCLUSIONS: The discrimination of mild cognitive impairment subtypes was possible only with the aid of a comprehensive neuropsychological assessment. It is necessary to develop new strategies for mild cognitive impairment screening in clinical practice.

Entities:  

Mesh:

Year:  2008        PMID: 19142405     DOI: 10.1590/s1516-44462008000400003

Source DB:  PubMed          Journal:  Braz J Psychiatry        ISSN: 1516-4446            Impact factor:   2.697


  15 in total

1.  Predicting risk of 2-year incident dementia using the CAMCOG total and subscale scores.

Authors:  Marialuisa Restaino; Fiona E Matthews; Thais Minett; Emiliano Albanese; Carol Brayne; Blossom Christa Maree Stephan
Journal:  Age Ageing       Date:  2013-07-19       Impact factor: 10.668

2.  Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer's disease.

Authors:  Antonio L Teixeira; Breno S Diniz; Alline C Campos; Aline S Miranda; Natalia P Rocha; Leda L Talib; Wagner F Gattaz; Orestes V Forlenza
Journal:  Neuromolecular Med       Date:  2012-09-28       Impact factor: 3.843

3.  Effects of a multidisciplinary cognitive rehabilitation program for patients with mild Alzheimer's disease.

Authors:  Luciane F Viola; Paula V Nunes; Monica S Yassuda; Ivan Aprahamian; Franklin S Santos; Glenda D Santos; Paula S Brum; Sheila M Borges; Alexandra M Oliveira; Gisele F S Chaves; Eliane C Ciasca; Rita C R Ferreira; Vanessa J R de Paula; Oswaldo H Takeda; Roberta M Mirandez; Ricky Watari; Deusivania V S Falcao; Meire Cachioni; Orestes V Forlenza
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

4.  Combining cognitive screening tests for the evaluation of mild cognitive impairment in the elderly.

Authors:  Rodolfo B Ladeira; Breno S Diniz; Paula V Nunes; Orestes V Forlenza
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

5.  Long-term lithium treatment reduces glucose metabolism in the cerebellum and hippocampus of nondemented older adults: an [¹⁸F]FDG-PET study.

Authors:  Orestes V Forlenza; Artur Martins Novaes Coutinho; Ivan Aprahamian; Silvana Prando; Luciana Lucas Mendes; Breno S Diniz; Wagner F Gattaz; Carlos A Buchpiguel
Journal:  ACS Chem Neurosci       Date:  2014-04-29       Impact factor: 4.418

6.  Low platelet iPLA₂ activity predicts conversion from mild cognitive impairment to Alzheimer's disease: a 4-year follow-up study.

Authors:  Wagner F Gattaz; Leda L Talib; Evelin L Schaeffer; Breno S Diniz; Orestes V Forlenza
Journal:  J Neural Transm (Vienna)       Date:  2013-09-15       Impact factor: 3.575

7.  Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer's disease.

Authors:  Isis A Zainaghi; Leda L Talib; Breno S Diniz; Wagner F Gattaz; Orestes V Forlenza
Journal:  J Neural Transm (Vienna)       Date:  2012-05-10       Impact factor: 3.575

8.  Neuropsychological markers of mild cognitive impairment: A clinic based study from urban India.

Authors:  Ravikesh Tripathi; Keshav Kumar; Rakesh Balachandar; P Marimuthu; Mathew Varghese; Srikala Bharath
Journal:  Ann Indian Acad Neurol       Date:  2015 Apr-Jun       Impact factor: 1.383

Review 9.  Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations.

Authors:  Sam T Creavin; Susanna Wisniewski; Anna H Noel-Storr; Clare M Trevelyan; Thomas Hampton; Dane Rayment; Victoria M Thom; Kirsty J E Nash; Hosam Elhamoui; Rowena Milligan; Anish S Patel; Demitra V Tsivos; Tracey Wing; Emma Phillips; Sophie M Kellman; Hannah L Shackleton; Georgina F Singleton; Bethany E Neale; Martha E Watton; Sarah Cullum
Journal:  Cochrane Database Syst Rev       Date:  2016-01-13

Review 10.  Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Craig Ritchie; Nadja Smailagic; Anna H Noel-Storr; Yemisi Takwoingi; Leon Flicker; Sam E Mason; Rupert McShane
Journal:  Cochrane Database Syst Rev       Date:  2014-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.